Atlas Trials

Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

Clinical trial NCT05549973 · UNKNOWN

Trial details

NCT number
NCT05549973
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2022-09-01
Primary completion
2023-07-01
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.